Stock listing

NASDAQ:GANX Gain Therapeutics, Inc. Stock

Home listing (NASDAQ) of Gain Therapeutics, Inc.

Follow Gain Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GANX

$0.999 USD -0.111 (-10.0%)

Close on Nov 20, 2026

Past year -64.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.970 – $1.099 USDNov 20, 2026
Volume
585,937 sharesNov 20, 2026
Market cap
$44.50M USDAt the close on Nov 20, 2026 · price × 44.53M shares outstanding
52-week range
$0.940 – $4.340 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$782,717 USDMedian day 383,023 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Gain Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GANX · Home$0.999 USD-0.111 (-10.0%)585,937$1.020$1.099$0.970$1.110Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GANX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.999-0.111-10.0%$1.020$1.099$0.970585,937
$1.110-0.070-5.9%$1.230$1.240$1.0801,156,199
$1.180+0.240+25.5%$0.980$1.300$0.9704,310,888
$0.940-0.100-9.6%$1.010$1.077$0.940591,261
$1.040-0.040-3.7%$1.120$1.135$1.010328,879
$1.080-0.030-2.7%$1.060$1.140$1.010300,382
$1.110+0.030+2.8%$1.120$1.160$1.070292,767
$1.080-0.010-0.9%$1.100$1.180$1.050411,687
$1.090+0.060+5.8%$1.020$1.115$1.000309,671
$1.030+0.070+7.2%$0.970$1.030$0.960328,332
$0.960-0.150-13.5%$1.100$1.121$0.940849,002
$1.110-0.040-3.5%$1.180$1.210$1.100228,583
$1.150+0.020+1.8%$1.130$1.190$1.130193,725
$1.1300.0000.0%$1.150$1.200$1.120268,674
$1.130-0.060-5.0%$1.180$1.195$1.110364,700
$1.190-0.005-0.4%$1.200$1.250$1.170177,200
$1.195+0.025+2.1%$1.160$1.200$1.160400,425
$1.170+0.020+1.7%$1.160$1.210$1.140508,340
$1.150-0.110-8.7%$1.280$1.280$1.140811,024
$1.260-0.030-2.3%$1.330$1.343$1.220645,033
$1.290+0.100+8.4%$1.180$1.330$1.1602,751,162
$1.1900.0000.0%$1.200$1.230$1.150609,772
$1.190-0.060-4.8%$1.230$1.295$1.170517,004
$1.250-0.010-0.8%$1.260$1.290$1.210532,167
$1.260-0.070-5.3%$1.320$1.377$1.235467,379
$1.330+0.010+0.8%$1.320$1.410$1.310510,815
$1.320-0.090-6.4%$1.370$1.420$1.295851,301
$1.410-0.160-10.2%$1.580$1.580$1.400799,935
$1.570-0.070-4.3%$1.650$1.650$1.565319,798
$1.640+0.025+1.5%$1.610$1.660$1.610328,689
$1.615-0.055-3.3%$1.660$1.675$1.610361,863
$1.6700.0000.0%$1.660$1.690$1.640373,931
$1.670-0.020-1.2%$1.700$1.750$1.655646,562
$1.690-0.020-1.2%$1.750$1.770$1.690351,043
$1.710-0.010-0.6%$1.750$1.780$1.700386,093
$1.720-0.010-0.6%$1.725$1.773$1.670497,407
$1.730+0.050+3.0%$1.700$1.840$1.690787,967
$1.680-0.090-5.1%$1.750$1.760$1.6001,289,905
$1.770-0.010-0.6%$1.750$1.820$1.720548,024
$1.780-0.060-3.3%$1.850$1.883$1.775383,023
$1.8400.0000.0%$1.840$1.855$1.790407,684
$1.840-0.110-5.6%$1.910$1.973$1.830292,877
$1.950+0.110+6.0%$1.850$1.960$1.825692,699
$1.840+0.080+4.5%$1.800$1.850$1.780335,860
$1.760-0.020-1.1%$1.790$1.805$1.750375,549
$1.780+0.060+3.5%$1.770$1.785$1.735341,535
$1.720+0.010+0.6%$1.730$1.790$1.700265,926
$1.710-0.030-1.7%$1.740$1.740$1.690215,693
$1.740-0.010-0.6%$1.760$1.800$1.730360,117
$1.750+0.040+2.3%$1.748$1.780$1.720223,559
$1.710-0.010-0.6%$1.720$1.740$1.690505,647
$1.720-0.110-6.0%$1.810$1.830$1.720513,385
$1.830+0.030+1.7%$1.800$1.850$1.770292,335
$1.800-0.020-1.1%$1.810$1.830$1.785205,350
$1.820+0.030+1.7%$1.800$1.825$1.770391,412
$1.790+0.020+1.1%$1.780$1.846$1.750367,689
$1.770-0.030-1.7%$1.830$1.830$1.770197,909
$1.800+0.030+1.7%$1.770$1.840$1.760259,893
$1.770-0.080-4.3%$1.840$1.855$1.760312,529
$1.850+0.040+2.2%$1.850$1.900$1.795416,109
$1.810-0.095-5.0%$1.910$1.920$1.800723,423
$1.905-0.095-4.7%$2.000$2.050$1.900383,518
$2.000-0.005-0.2%$2.010$2.030$1.930315,900
$2.005+0.025+1.3%$2.000$2.045$1.980277,476
$1.980-0.090-4.3%$2.030$2.035$1.950382,528
Ticker
NASDAQ:GANX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Gain Therapeutics, Inc. news

Gain Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 118 in all · newest Nov 17, 2026 · oldest 2021
Decks
33 decks · latest October 2026

Where Gain Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GANX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GANXBOATSUnited StatesUSD

Valuation

Price/book 4.4× against a median of 5.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$33.11M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.60

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Gain Therapeutics, Inc. · NASDAQ:GANXUS$44.50MUS$33.11Mn/an/an/a4.4×n/a0.0×1.60
MegaPro Biomedical Co., Ltd. · TPEX:6827US$45.95MUS$43.30Mn/an/an/a7.0×n/a0.0×n/a
SunBio, Inc. · KRX:067370US$45.82MUS$42.92M14.2×4.6×8.9×2.0×34.6%0.0×n/a
Apollomics Inc. · NASDAQ:APLMUS$45.28MUS$42.65Mn/a5.0×n/an/a−128.7%n/a1.02
Zelluna ASA · OSL:ZLNAUS$45.02MUS$38.83Mn/an/an/a5.1×n/a0.0×n/a
Oncoinvent ASA · OSL:ONCINUS$44.76MUS$33.80Mn/a14.3×n/a5.4×−673.1%0.0×n/a
ImageneBio, Inc. · NASDAQ:IMAUS$44.50M−US$80.79Mn/an/an/a0.3×n/a0.0×0.52
Annovis Bio, Inc. · NYSE:ANVSUS$44.12MUS$41.30Mn/an/an/an/an/an/a2.53
Arch Biopartners, Inc. · TSXV:ARCHUS$44.06MUS$44.06Mn/an/an/an/an/an/a0.94
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Median of the othersUS$44.63MUS$40.06M14.2×4.8×8.9×5.1×−99.9%0.0×1.02

Forecasts

4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
7.20 USD · Analysts' mean
EPS, year to Dec 2026
-0.41 · 1 analyst

Team and board

Officers

OfficerRole
Gene MackChief Executive Officer
Apaar JammuDirector, Investor Relations and Public Relations
Investors:Gain TherapeuticsInc. Apaar Jammu Director, Investor Relations and Public

Board

DirectorRole
Khalid IslamChairman
Claude NicaiseIndependent Member
Dov GoldsteinIndependent Member
Gene MackChief Executive Officer
Gwen MelincoffIndependent Member
Hans Peter HaslerIndependent Member
Jeffrey RileyIndependent Member

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+2.8%
Q2 2026Aug 11, 2026 · After close+2.9%
Q1 2026May 11, 2026 · After close−1.1%
Q4 2025Mar 19, 20260.0%
Q3 2025Nov 12, 2025 · After close+1.4%
Q2 2025Aug 12, 2025 · After close+1.3%
Q1 2025May 14, 2025 · After close−2.7%
Q4 2024Mar 24, 2025 · Before open−0.8%
Q3 2024Nov 14, 2024 · After close+5.7%
Q2 2024Aug 8, 2024 · After close+1.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+12.0%
Q4 2023Mar 26, 2024 · Before open+4.1%
Q3 2023Nov 14, 2023 · After close+4.3%
Q2 2023Aug 10, 2023 · After close−0.8%
Q1 2023May 12, 2023 · Before open+0.4%
Q4 2022Mar 23, 2023 · After close+1.2%
Q3 2022Nov 10, 2022 · After close+1.3%
Q2 2022Aug 8, 2022 · Before open+5.0%
Q1 2022May 16, 2022 · After close0.0%
Q4 2021Mar 25, 2022 · After close−5.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck27 slidesOctober 2026
Investor Presentation (September 2026)Investor deck27 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck26 slidesAugust 2026
Investor Presentation (July 2026)Investor deck27 slidesJuly 2026
Investor Presentation (June 2026)Investor deck25 slidesJune 2026
Investor Presentation (May 2026)Investor deck24 slidesMay 2026
Investor Presentation (March 2026)Investor deck25 slidesMarch 2026
Investor Presentation (March 2026)Investor deck24 slidesMarch 2026
Investor Presentation (February 2026)Investor deck19 slidesFeb 3, 2026
Investor Presentation (February 2026)Investor deck19 slidesFebruary 2026
All 33 decks
DeckKindSlidesDate
Technical Presentation (January 2026)Technical36 slidesJan 6, 2026
Investor Presentation (January 2026)Investor deck21 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck20 slidesNovember 2025
Technical Presentation (October 2025)Technical33 slidesOct 14, 2025
Investor Presentation (October 2025)Investor deck24 slidesOctober 2025
Investor Presentation (June 2025)Investor deck31 slidesJune 2025
Investor Presentation (May 2025)Investor deck33 slidesMay 2025
Technical Presentation (April 2025)Technical15 slidesApril 2025
Investor Presentation (April 2025)Investor deck29 slidesApril 2025
Investor Presentation (April 2025)Investor deck32 slidesApril 2025
Investor Presentation (February 2025)Investor deck29 slidesFebruary 2025
Investor Presentation (December 2024)Investor deck28 slidesDecember 2024
Investor Presentation (November 2024)Investor deck30 slidesNovember 2024
Investor Presentation (October 2024)Investor deck31 slidesOctober 2024
Investor Presentation (October 2024)Investor deck29 slidesOctober 2024
Investor Presentation (September 2024)Investor deck23 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck23 slidesAugust 2024
Investor Presentation (February 2024)Investor deck28 slidesFebruary 2024
Investor Presentation (October 2023)Investor deck19 slidesOct 18, 2023
Investor Presentation (2023)Investor deck22 slides2023
Investor Presentation (May 2022)Investor deck44 slidesMay 2022
Investor Presentation (August 2021)Investor deck40 slidesAugust 2021
Investor Presentation (May 2021)Investor deck40 slidesMay 4, 2021

Open Decks

Financings

RaiseDate
Public offering of shares of common stock and warrants to purchase common stock
Announced: about US$7M · US$3.11 a share · 1 warrant at US$1.65 for 60 months · Newbridge Securities Corporation
Dealers: Newbridge Securities Corporation (lead)
Use of proceeds: Clinical and nonclinical development of lead candidate GT-02287 for neurodegenerative diseases including GBA1 Parkinson's, and general corporate purposes
Jul 16, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$11.00 a share on Mar 17, 2021.

Price
US$11.00 a share
Shares offered
3,636,364 shares of common stock
Offering size
US$40 million
Underwriters' option
Up to 545,454 more shares
Listing
GANX on the Nasdaq Global Market
Underwriters
BTIG, Oppenheimer & Co., National Securities Corporation · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceNov 16, 2020
Filed publiclyFeb 19, 2021
Amended twiceNewest Mar 15, 2021
Shares registered with an exchangeMar 17, 2021
Declared effective by the SECMar 17, 2021
Final prospectus, with the priceMar 22, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Mar 22, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0055.2K140.1K165.0K28.9K41.3K20.6K
Cost of revenue94.0K84.1K80.4K8.24M7.16M2.26M
Gross profit-94.0K-84.1K55.2K140.1K165.0K28.9K41.3K20.6K
Research and development10.2M10.8M11.5M8.38M7.16M2.26M1.59M826.9K
Selling, general and administrative8.50M9.56M10.8M9.54M6.83M1.25M555.2K222.0K
Operating income-18.7M-20.4M-22.3M-17.8M-13.8M-3.48M-2.10M-1.03M
Depreciation and amortization94.0K84.1K83.6K64.2K15.5K9.59K2.57K741
EBITDA-18.6M-20.3M-22.2M-17.7M-13.8M-3.47M-2.10M-1.03M
Interest expense247.4K0189.3K20.5K52.5K
Income before tax-19.3M-19.9M-22.2M-17.5M-13.9M-3.57M-2.19M-1.10M
Income tax861.1K536.8K79.3K93.0K4.01K5.39K7.11K9.78K
Net income-20.2M-20.4M-22.3M-17.6M-13.9M-3.58M-2.19M-1.11M
Earnings per share, basic-0.61-0.89-1.71-1.48-1.37-1.33-0.26-0.19
Earnings per share, diluted-0.61-0.89-1.71-1.48-1.37-1.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents20.8M10.4M11.8M7.31M36.9M7.49M303.3K400.7K
Short-term investments05.00M12.8M0
Receivables802.7K765.8K242.6K103.9K195.4K8.55K44.9K41.8K
Inventory1.36M31.5K
Current assets22.2M11.6M17.8M21.1M37.7M8.99M398.0K494.6K
Property, plant and equipment74.9K103.6K126.0K144.4K106.0K29.6K219.3K305.8K
Total assets22.8M12.1M18.6M24.1M39.0M9.60M660.3K811.6K
Accounts payable825.0K946.3K1.32M1.63M560.5K961.5K154.4K149.3K
Current liabilities3.35M3.91M4.95M4.13M2.55M2.11M879.1K530.8K
Long-term debt300.1K328.3K449.1K495.3K590.5K715.7K
Total debt401.0K438.5K567.9K603.4K694.3K738.3K200.9K1.31M
Total liabilities4.25M4.78M6.03M5.22M4.17M3.40M1.11M1.76M
Shareholders' equity18.6M7.34M12.6M18.9M34.8M6.20M-449.9K-950.9K
Shares outstanding42.1M27.1M16.2M11.9M11.9M3.54M8.37M5.86M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-18.5M-18.9M-18.9M-14.7M-12.4M-3.24M-1.87M-744.5K
Capital spending-2-22.5K-15.4K-119.0K-94.2K-20.8K-13.7K-7.99K
Free cash flow-18.5M-18.9M-18.9M-14.8M-12.5M-3.26M-1.88M-752.5K
Cash from investing4.98M10.2M-14.8M-94.2K-20.8K-13.7K-7.99K
Cash from financing28.4M13.0M12.6M-78.8K41.8M10.5M1.75M983.8K
Change in cash10.5M-1.41M4.49M-29.6M29.4M7.19M-97.2K237.9K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 17, 2026Current reportSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 30, 2026Insider tradeSEC
8-K · Current reportOct 28, 2026Management or board changeSEC
8-K · Current reportOct 1, 2026Current reportSEC
8-K · Current reportSep 28, 2026Management or board changeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
8-K · Current reportJul 16, 2026Current reportSEC
8-K · Current reportJun 29, 2026Current reportSEC
8-K · Current reportJun 25, 2026Meeting outcomeSEC
8-K · Current reportMay 26, 2026Current reportSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 18, 2026Current reportSEC
8-K · Current reportFeb 3, 2026Current reportSEC
8-K · Current reportDec 18, 2025Current reportSEC
S-8 · Registration statement for employee plansDec 3, 2025Offer documentSEC
8-K · Current reportNov 28, 2025Current reportSEC
424B5 · ProspectusNov 28, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
S-3/A · Registration statement, amendedNov 7, 2025Offer documentSEC
8-K · Current reportOct 14, 2025Current reportSEC
8-K · Current reportOct 9, 2025Management or board changeSEC
8-K · Current reportOct 6, 2025Current reportSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
424B5 · ProspectusJul 17, 2025Offer documentSEC
8-K · Current reportJul 17, 2025Material contractSEC
424B5 · ProspectusJul 15, 2025Offer documentSEC
8-K · Current reportJun 30, 2025Current reportSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
8-K · Current reportJun 24, 2025Meeting outcomeSEC
UPLOAD · Letter from the SECJun 4, 2025Other filingsSEC
S-3 · Registration statementMay 28, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2025Meeting noticeSEC
8-K · Current reportApr 10, 2025Current reportSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
8-K · Current reportFeb 6, 2025Current reportSEC
8-K · Current reportJan 15, 2025Current reportSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
8-K · Current reportJan 7, 2025Management or board changeSEC
8-K · Current reportDec 23, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
8-K · Current reportOct 21, 2024Current reportSEC
8-K · Current reportOct 8, 2024Current reportSEC
S-8 · Registration statement for employee plansSep 19, 2024Offer documentSEC
424B5 · ProspectusSep 6, 2024Offer documentSEC
8-K · Current reportSep 6, 2024Material contractSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJul 12, 2024Current reportSEC
8-K · Current reportJul 9, 2024Current reportSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
FWP · Free writing prospectusJul 1, 2024Offer documentSEC
8-K · Current reportJun 28, 2024Management or board changeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
8-K · Current reportJun 25, 2024Meeting outcomeSEC
424B5 · ProspectusJun 17, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Material contractSEC
424B5 · ProspectusJun 13, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
4 · Change in ownershipApr 8, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 8, 2024Insider tradeSEC
8-K · Current reportApr 8, 2024Management or board changeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
8-K · Current reportMar 26, 2024ResultsSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
8-K · Current reportFeb 22, 2024Management or board changeSEC
8-K · Current reportJan 31, 2024Current reportSEC
424B3 · ProspectusJan 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 2, 2024Other filingsSEC
4 · Change in ownershipDec 22, 2023Insider tradeSEC
CORRESP · Letter to the SECDec 22, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 21, 2023Other filingsSEC
S-1 · Registration statementDec 19, 2023Offer documentSEC
4 · Change in ownershipDec 14, 2023Insider tradeSEC
424B5 · ProspectusNov 24, 2023Offer documentSEC
8-K · Current reportNov 22, 2023Material contractSEC
424B5 · ProspectusNov 20, 2023Offer documentSEC
8-K · Current reportNov 17, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipSep 22, 2023Insider tradeSEC
4 · Change in ownershipSep 22, 2023Insider tradeSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
8-K · Current reportJun 23, 2023Meeting outcomeSEC
S-8 · Registration statement for employee plansMay 26, 2023Offer documentSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 12, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 28, 2023Management or board changeSEC
4 · Change in ownershipApr 12, 2023Insider tradeSEC
3 · Initial statement of ownershipApr 12, 2023Insider tradeSEC
8-K · Current reportApr 12, 2023Management or board changeSEC
4 · Change in ownershipMar 27, 2023Insider tradeSEC
4 · Change in ownershipMar 27, 2023Insider tradeSEC
4 · Change in ownershipMar 27, 2023Insider tradeSEC
10-K · Annual reportMar 23, 2023Annual reportSEC
8-K · Current reportMar 23, 2023ResultsSEC
3 · Initial statement of ownershipDec 21, 2022Insider tradeSEC
8-K · Current reportDec 16, 2022Management or board changeSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
4 · Change in ownershipSep 22, 2022Insider tradeSEC
8-K · Current reportSep 20, 2022Management or board changeSEC
10-Q · Quarterly reportAug 8, 2022Quarterly reportSEC
8-K · Current reportAug 8, 2022ResultsSEC
4 · Change in ownershipJul 19, 2022Insider tradeSEC
4 · Change in ownershipJul 19, 2022Insider tradeSEC
S-8 · Registration statement for employee plansJul 15, 2022Offer documentSEC
8-K · Current reportJun 17, 2022Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveJun 2, 2022Other filingsSEC
CORRESP · Letter to the SECMay 31, 2022Other filingsSEC
4 · Change in ownershipMay 27, 2022Insider tradeSEC
4 · Change in ownershipMay 23, 2022Insider tradeSEC
S-3/A · Registration statement, amendedMay 23, 2022Offer documentSEC
4/A · Change in ownership, amendedMay 23, 2022Insider tradeSEC
UPLOAD · Letter from the SECMay 20, 2022Other filingsSEC
4 · Change in ownershipMay 19, 2022Insider tradeSEC
S-3 · Registration statementMay 18, 2022Offer documentSEC
10-Q · Quarterly reportMay 16, 2022Quarterly reportSEC
8-K · Current reportMay 16, 2022ResultsSEC
DEF 14A · Proxy statementMay 13, 2022Meeting noticeSEC
10-K/A · Annual report, amendedMay 2, 2022Annual reportSEC
4/A · Change in ownership, amendedApr 21, 2022Insider tradeSEC
3/A · Initial statement of ownership, amendedApr 21, 2022Insider tradeSEC
10-K · Annual reportMar 25, 2022Annual reportSEC
8-K · Current reportMar 24, 2022ResultsSEC
4 · Change in ownershipDec 28, 2021Insider tradeSEC
3 · Initial statement of ownershipDec 28, 2021Insider tradeSEC
8-K · Current reportDec 28, 2021Management or board changeSEC
10-Q · Quarterly reportNov 12, 2021Quarterly reportSEC
8-K · Current reportNov 12, 2021ResultsSEC
8-K · Current reportOct 20, 2021Management or board changeSEC
4 · Change in ownershipAug 17, 2021Insider tradeSEC

This page holds 200 of 243 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Gain Therapeutics, Inc.’s releases · as of Oct 30, 2026

Common shares
44,525,347
Fully diluted
44,525,347

Fully diluted

LineSharesAs of
Common shares44,525,347Oct 30, 2026

Share count over time

CountShares
Oct 30, 202644,525,347
Sep 30, 202644,324,134

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Marshall Wace, LLP1.68M3.8%US$2.91MSep 30, 2026
Potomac Capital Management, Inc.930K2.1%US$1.61MSep 30, 2026
Jones Financial Companies Lllp739K1.7%US$1.32MSep 30, 2026
Vanguard730K1.6%US$1.26MSep 30, 2026
Gsa Capital Partners LLP635K1.4%US$1.1MSep 30, 2026
Cambridge Investment Research Advisors, Inc.567K1.3%US$980KSep 30, 2026
DME Capital Management, LP566K1.3%US$979KSep 30, 2026
Geode Capital470K1.1%US$813KSep 30, 2026
BlackRock268K0.60%US$464KSep 30, 2026
UBS241K0.54%US$418KSep 30, 2026
All 48 holders
HolderSharesOf the companyValueAs of
Cresset Asset Management, LLC220K0.49%US$381KSep 30, 2026
State Street200K0.45%US$345KSep 30, 2026
Renaissance Technologies183K0.41%US$316KSep 30, 2026
Citadel170K0.38%US$294KSep 30, 2026
LPL Financial LLC117K0.26%US$203KSep 30, 2026
Morgan Stanley106K0.24%US$183KSep 30, 2026
Northern Trust97,0130.22%US$168KSep 30, 2026
Commonwealth Equity Services, LLC57,8810.13%US$100KSep 30, 2026
Empowered Funds, LLC52,2380.12%US$90,372Sep 30, 2026
Bridgeway Capital Management, LLC52,2380.12%US$90,372Sep 30, 2026
Prelude Capital Management, LLC35,8200.08%US$61,969Sep 30, 2026
Apollon Wealth Management, LLC31,5000.07%US$54,495Sep 30, 2026
Simplex Trading, LLC28,4570.06%US$49,230Sep 30, 2026
StoneX Group Inc.25,1180.06%US$43,908Sep 30, 2026
Oliver Luxxe Assets LLC20,2500.05%US$35,033Sep 30, 2026
Bokf, NA20,0000.04%US$34,600Sep 30, 2026
HighTower Advisors, LLC17,1740.04%US$29,711Sep 30, 2026
Wealth Enhancement Advisory Services, LLC17,0560.04%US$27,545Sep 30, 2026
Wealthspire Advisors, LLC16,9000.04%US$29,237Sep 30, 2026
JPMorgan15,9600.04%US$26,813Sep 30, 2026
Sandhill Capital Partners LLC15,4000.03%US$26,642Sep 30, 2026
Crux Wealth Advisors14,9250.03%US$16,268Sep 30, 2026
Hrt Financial LP14,9030.03%US$25,000Sep 30, 2026
Benedict Financial Advisors Inc13,5000.03%US$23,355Sep 30, 2026
HB Wealth Management, LLC12,7830.03%US$22,115Sep 30, 2026
R Squared Ltd11,5840.03%US$20,040Sep 30, 2026
Harbour Investments, Inc.10,7450.02%US$18,589Sep 30, 2026
NewEdge Advisors, LLC10,6000.02%US$18,338Sep 30, 2026
Mercer Global Advisors Inc10,0000.02%US$17,300Sep 30, 2026
Sanctuary Advisors, LLC10,0000.02%US$17,300Sep 30, 2026
Tower Research Capital LLC (TRC)4,7280.01%US$8,180Sep 30, 2026
RBC2,278<0.01%US$4,000Sep 30, 2026
Arax Advisory Partners1,700<0.01%US$2,941Sep 30, 2026
Wells Fargo1,000<0.01%US$1,730Sep 30, 2026
Pinnacle Financial Group, Inc.600<0.01%US$1,038Sep 30, 2026
Caitong International Asset Management Co., Ltd101<0.01%US$175Sep 30, 2026
Larson Financial Group LLC10<0.01%US$17Sep 30, 2026
Barclays2<0.01%US$3Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund431K0.97%US$875KJun 30, 2026
Fidelity Extended Market Index Fund207K0.47%US$404KMay 31, 2026
iShares Micro-Cap ETF144K0.32%US$293KJun 30, 2026
Fidelity Total Market Index Fund57,3350.13%US$112KMay 31, 2026
Fidelity Series Total Market Index Fund55,6360.12%US$108KMay 31, 2026
Ultra-Small Company Market Fund30,0040.07%US$60,908Jun 30, 2026
Fidelity Nasdaq Composite Index Fund28,6290.06%US$55,827May 31, 2026
1290 VT Micro Cap Portfolio9,7300.02%US$19,752Jun 30, 2026
Total Stock Market Index Trust966<0.01%US$1,961Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dov Goldstein
Other companies: BioAge Labs, Inc. (Chief Financial Officer · Since at least Sep 25, 2024); Coya Therapeutics, Inc. (Director · Since at least Dec 28, 2022); NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2022 · Past); Loxo Oncology Inc (CFO and Treasurer · Jul 31, 2014 – Apr 1, 2015 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – Jun 6, 2018 · Past); Durata Therapeutics Inc (Director · Jul 18, 2012 – Jul 24, 2012 · Past); ADMA Biologics Inc (Director · Feb 13, 2012 – Feb 28, 2020 · Past); Cempra Inc (Director · Feb 2, 2012 – Mar 7, 2017 · Past)
Independent Member · Since at least Mar 17, 2021
Charles Evan Ballantyne
Other companies: Agenus Inc. (CFO · Jun 17, 2015 – Jun 14, 2016 · Past); Theriva Biologics, Inc. (Chief Financial Officer · Feb 6, 2012 – Jan 8, 2015 · Past); Clinical Data Inc (EVP, CFO · Jun 14, 2007 – Apr 12, 2011 · Past)
Chief Financial Officer · Apr 10, 2023 – Apr 10, 2023 · Past
Khalid Islam
Other companies: Fennec Pharmaceuticals Inc. (Chairman · Since at least Sep 11, 2017); Processa Pharmaceuticals, Inc. (Director · Nov 3, 2020 – Mar 31, 2022 · Past); Immunomedics Inc (Director · Mar 13, 2017 – Oct 23, 2020 · Past)
Chairman · Since at least Mar 17, 2021
Eric I Richman
Other companies: NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2022 · Past); ADMA Biologics Inc (Director · Nov 9, 2017 – Feb 28, 2020 · Past)
Director · Since at least Mar 17, 2021
Hans Peter Hasler
Other companies: Minerva Neurosciences, Inc (Member · Since at least Dec 10, 2017); Patheon N.V. (Director · Jul 20, 2016 – Aug 29, 2017 · Past)
Director · Since at least Mar 17, 2021
Gene Mack
Other companies: SELLAS Life Sciences Group, Inc. (CFO and Treasurer · Apr 20, 2018 – Apr 20, 2018 · Past)
Chief Executive Officer · Since at least Apr 5, 2024
Jeffrey Riley
Other companies: Theriva Biologics, Inc. (Chief Executive Officer, Director · Mar 16, 2010 – Nov 30, 2016 · Past)
Independent Member · Since at least Mar 17, 2021
Apaar JammuDirector, Investor Relations and Public Relations · Since at least Oct 8, 2026
Claude NicaiseIndependent Member · Since at least Nov 5, 2026
Gianluca FuggettaSee Remark · Since at least Dec 12, 2022
All 14 people
PersonSeat
Gwen MelincoffIndependent Member · Since at least Nov 5, 2026
Investors:Gain TherapeuticsInc. Apaar Jammu Director, Investor Relations and Public · Since at least Oct 1, 2026
Manolo BellottoPresident and General Manager · Mar 17, 2021 – Mar 17, 2021 · Past
Salvatore CalabreseChief Financial Officer · Mar 17, 2021 – Mar 23, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Gain Therapeutics, Inc.